These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer. Kang CM; Hwang HK; Choi SH; Lee WJ Surg Oncol; 2013 Jun; 22(2):123-31. PubMed ID: 23518243 [TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267 [TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer. Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394 [TBL] [Abstract][Full Text] [Related]
28. Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment. Nipp RD; Zanconato A; Zheng H; Ferrone CR; Lillemoe KD; Wo JY; Hong TS; Clark JW; Ryan DP; Fernández-Del Castillo C Pancreas; 2017 Feb; 46(2):183-189. PubMed ID: 27846142 [TBL] [Abstract][Full Text] [Related]
29. Can we move towards personalised pancreatic cancer therapy? Jamieson NB; Chang DK; Grimmond SM; Biankin AV Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):335-8. PubMed ID: 24702631 [No Abstract] [Full Text] [Related]
31. What is the major prognostic factor in tumor-node-metastasis staging of pancreatic adenocarcinoma? Santi I; Brandt A; Hemminki K Ann Surg Oncol; 2011 Jan; 18(1):300-1. PubMed ID: 20589435 [No Abstract] [Full Text] [Related]
32. Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific siRNA inhibits the growth of cancer cells. Gao DJ; Xu M; Zhang YQ; Du YQ; Gao J; Gong YF; Man XH; Wu HY; Jin J; Xu GM; Li ZS Pancreas; 2010 Oct; 39(7):994-1001. PubMed ID: 20467347 [TBL] [Abstract][Full Text] [Related]
33. Negative impact of fresh-frozen plasma transfusion on prognosis of pancreatic ductal adenocarcinoma after pancreatic resection. Shiba H; Misawa T; Fujiwara Y; Futagawa Y; Furukawa K; Haruki K; Iida T; Iwase R; Yanaga K Anticancer Res; 2013 Sep; 33(9):4041-7. PubMed ID: 24023348 [TBL] [Abstract][Full Text] [Related]
34. [Evolution in the therapeutic strategy of localized resectable pancreatic ductal adenocarcinoma]. Van Daele D; Puleo F; Dumont R; Polus M; Loly C; Martinive P; Meunier P; Collignon J; Hendlisz A; Maréchal R; Louis E; Van Laethem JL Rev Med Suisse; 2015 Aug; 11(483):1543-8. PubMed ID: 26502580 [TBL] [Abstract][Full Text] [Related]
35. Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma. Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakashima A; Sueda T J Surg Oncol; 2009 Jul; 100(1):13-8. PubMed ID: 19384908 [TBL] [Abstract][Full Text] [Related]
36. [Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects]. Ye C; Zheng L; Yuan CH Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):10-15. PubMed ID: 30612387 [TBL] [Abstract][Full Text] [Related]